Looking for materials to share with patients?
NewBeauty, a sister brand of HCPLive, offers consumer-friendly coverage of chronic spontaneous urticaria and other chronic skin conditions, including atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, and alopecia.
The FDA approved remibrutinib on September 30, 2025, for adults with CSU who remain symptomatic despite H1 antihistamine treatment, based on the phase 3 REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) trials.1 An indirect analysis has since suggested omalizumab and remibrutinib produce similar early gains in CSU.2 Craig noted most CSU is now considered autoimmune rather than allergic, driven by antibodies against IgE or the mast cell.
Craig begins with a once-daily second-generation antihistamine, such as cetirizine or fexofenadine, and escalates per guidelines to 2 tablets twice daily for a few weeks before moving on. He defers laboratory workup, including complete blood count, chemistry panel, C-reactive protein, erythrocyte sedimentation rate, thyroid-stimulating hormone, and thyroid antibodies, until patients fail updosing, as results are almost always normal. His treatment goal is complete absence of hives with no interference in quality of life, and sleep disturbance is a common reason patients seek care.
Among advanced therapies, omalizumab binds IgE to reduce mast cell activation, dupilumab lowers IgE and blocks other cytokines, and remibrutinib inhibits BTK to reduce histamine release. Craig described all 3 as effective, with remibrutinib and omalizumab offering rapid onset, often within days to weeks, while dupilumab works more slowly. Omalizumab retains advantages in its long history of use in pregnancy and its capacity for updosing to as high as 600 mg every 2 weeks.